DiagnaMed Holdings Corp. · CSE:DMED
DiagnaMed — Investor Presentation (November 2024)
14 slides from DiagnaMed's investor presentation, November 2024
Slide 1: DiagnaMed Holdings Corp. Corporate Presentation
DiagnaMed Holdings Corp. Corporate Presentation NOVEMBER 2024 CSE: DMED | OTCQB: DGNMF
Slide 2: Unlocking the Potential of Hydrogen
Unlocking the Potential of Hydrogen Global hydrogen generation market est USD 170 billion (2023) and expected CAGR of 9.3% from 2024 to 2030 Industrial Medical
Slide 3: EIREX Water to Hydrogen Technology
EIREX Water to Hydrogen Technology DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 4: EIREX
EIREX Collaboration with EIREX in developing a novel modular carbon-free technology that extracts hydrogen from water Solving the problems faced by producing hydrogen via electrolysis Scalable solution will offer on-site hydrogen EIREX’s approach uses the unique production in various sizes, from 50
Slide 5: EIREX Key Benefits
EIREX Key Benefits Low Cost: Produces hydrogen at less than 1.4 kWh per kg, significantly reducing costs. On-Demand: Minimizes hydrogen storage requirements. On-Site Production: Eliminates the need for extensive distribution infrastructure. Self-Powered: Operates without reliance on external grid en
Slide 6: Unlocking the Medical Potential of Hydrogen
Unlocking the Medical Potential of Hydrogen DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 7: Molecular Hydrogen
Molecular Hydrogen Molecular hydrogen therapy is a rapidly growing field and poised for clinical adoption Over 2,000 scientific publications on potential therapeutic effects in over 100 human studies Clinically demonstrated to provide antioxidant, anti- inflammatory and neuroprotective effects Diagn
Slide 8: Potential Medical Uses of Hydrogen
Potential Medical Uses of Hydrogen Our Current Focus Brain Dementia Parkinson’s disease Depression Alzheimer’s disease TBI/Concussions Stroke Stroke Aging Ischemia/reperfusion injuries Inflammation Metabolic Syndrome Side effects by cancer drugs Organ Transplants Sepsis Diabetes Radiotherapy Post-ca
Slide 9: Clinical Validation
Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 10: Limitations of Molecular Hydrogen
Limitations of Molecular Hydrogen Clinical use is limited primarily due to its: Low hydrogen content Rapid evaporating action in water Lower effective concentration and poor stability Hydrogen inhalation and hydrogen-rich water machines are: Expensive, bulky and complex to use Challenging to determi
Slide 11: Our Solution
Our Solution HydroPharm™ - novel ‘patent-pending’ oral molecular hydrogen tablet tailored for mental health and neurological disorders Offering different doses, durations, and methods of administration HydroPharm™ Hydrogen producing oral tablets License technology that enable natural hydrogen to mee
Slide 12: Team
Team Management Board Fabio Chianelli Fabio Chianelli Founder, Chairman, and CEO Founder, Chairman, and CEO Founder, CEO - PharmaTher Founder, CEO - PharmaTher Founder, President - Revive Thera Founder, President - Revive Thera Ming Jang, CPA, CGA Jing Peng, CPA Director Director of various pubco's
Slide 13: Financial Snapshot
Financial Snapshot 80,052,640 2,000,000 Common Shares outstanding Stock Options 37,382,226 Common Shares are subject to escrow 1/10th released at: November 8, 2023, 2024, 2025 ~ 21% May 8, 2024, 2025, 2026 2/10th released at: Insider Ownership November 8, 2026
Slide 14: Thank You
THANK YOU DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 t. 416-800-2684 e. info@diagnamed.com DiagnaMed CSE: DMED | OTCQB: DGNMF
DiagnaMed Holdings — Investor Presentation (November 2024) on 6ix